Exploring clinical trials for breast cancer

Matthew P. Goetz, M.D., a medical oncologist at Mayo Clinic's campus in Rochester, Minnesota, discusses the newest innovations and updates in breast cancer clinical trials. In a recent advancement, Mayo Clinic collaborated with the National Cancer Institute to develop formulations of endoxifen. The drug had substantial anti-tumor activity in women whose cancers had previously progressed on standard hormonal therapy.

Mayo Clinic is increasingly ordering genetic tests on a regular basis for patients, which can substantially help patients with decision-making.


July 30, 2020

Created by

Mayo Clinic

Related Presenters

Matthew Goetz, MD

Matthew Goetz, MD

Conditions treated Breast cancer Procedures performed Pharmacogenomic testing Interests Pharmacogenomics of breast cancer Biomarkers of endocrine response Breast cancer drug development in endocrine responsive ...

View full profile